The use of cell salvage during second-stage reimplantation for the treatment of chronic hip periprosthetic joint infection: a retrospective cohort study

Table 4 Clinical data for second-stage reimplantation. Numbers indicate median (25th–75th percentile)

Viable	Cell salvage reinfused group	Control group	P-value
Viable	(n = 61)	(n = 64)	P-value
Hemoglobin (g/l)
Preoperative	137 (130–142)	136 (131–143)	.694^a
Day 1	108 (99–117)	105 (94–112)	.112^a
Hematocrit (%)
Preoperative	41 (40–42)	41 (39–43)	.919^a
Day 1	32 (27–35)	32 (28–35)	.804^a
Estimated blood loss (ml)	846 (623–1230)	1195 (861 to 1474)	.002^a
Reinfused blood (ml)	300 (200–750)	–
Allogeneic RBC transfused (units)	2.0 (1.5–2.0)	1.5 (1.5–2.0)	.630^a
Allogeneic RBC transfused, n (%)	7 (11.5%)	17 (26.6%)	.041^b
Plasma transfused (ml)	300 (163–1712)	200 (200–400)	.896^a
Plasma transfused, n (%)	4 (6.6%)	5 (7.8%)	1.000^b
Duration of operation (min)	159 (143–180)	156 (130–175)	.128^a
Length of hospitalization (days)	11 (9–14)	12 (10–18)	.045^a

ISSN: 1749-799X